(Q41783949)

English

Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report

scientific article published on 29 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report (English)

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

author name string

Hadi Alphonse Goubran

1

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

language of work or name

0 references

publication date

29 April 2009

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Journal of Medical Case Reports

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

7112

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

copyright license

Creative Commons Attribution 3.0 Unported

29 April 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1752-1947-3-7112

0 references

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726486

6 June 2018

The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726486

6 June 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726486

6 June 2018

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726486

18 August 2018

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726486

18 August 2018

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

1 reference

https://api.crossref.org/works/10.1186%2F1752-1947-3-7112

21 January 2018

Identifiers

10.1186/1752-1947-3-7112

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1752-1947-3-7112

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41783949&oldid=1802042733"